Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP017
- Development stage
- Phase 1
- Lead developer
- Anyuan Pharmaceutical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (injection)
01
Overview
AP017 is a monoclonal antibody developed by Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd. It is currently in Phase 1 clinical development, with its primary indications being Hemophilia A and Hemophilia B. The drug is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics in healthy subjects through single-dose escalation studies. The precise molecular target and mechanism of action have not been disclosed publicly as of the latest available data[1].
- Other names
- AP017单克隆抗体
Beyond the preview
Go deeper on AP017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP017.